NCT06910527 (PLAKID-TRANSP) is a clinical trial in Transplant Rejection, sponsored by Poulet Geoffroy.

Who is sponsoring NCT06910527?

NCT06910527 is sponsored by Poulet Geoffroy.

What condition does NCT06910527 study?

NCT06910527 studies Transplant Rejection, Transplant Kidney.

Is NCT06910527 still recruiting?

NCT06910527 is currently recruiting now. Last updated 4 April 2025.

Last reviewed 2025-04-04 · How we verify

NCT06910527: PLAKID-TRANSP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Plasma and Urinary cfDNA of in Kidney Transplant Patients

Recruiting now Last updated 4 April 2025

What this trial tests

trial in Transplant Rejection in 250 participants. Currently enrolling.

Timeline

30 May 2024

Primary endpoint
31 May 2025

31 May 2026

Quick facts

Lead sponsor	Poulet Geoffroy
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	250
Start date	30 May 2024
Primary completion	31 May 2025
Estimated completion	31 May 2026
Sites	1 location across France

Conditions studied

Transplant Rejection — all drugs for Transplant Rejection →
Transplant Kidney — all drugs for Transplant Kidney →

Sponsor

Poulet Geoffroy

Who can join

18 and older, any sex, with Transplant Rejection or Transplant Kidney. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It has been shown that the amount of circulating donor-cell-free DNA increases in patients with transplant rejection. Quantification of single nucleotide polymorphisms (SNPs) present in circulating donor DNA currently allows for early identification of transplant rejection, but not for characterization, i.e., identification of the affected renal fraction of the graft. Recently, in healthy subjects, teams have shown that it is possible to identify the tissue origin of donor-cell-free DNA, based on the epigenetic properties of circulating DNA. CGenetix is a MedTech company developing an in vitro diagnostic medical device to identify and quantify kidney graft degradation during transplant rejection. The objective of this study is to evaluate the sensitivity of the proposed technology to detect circulating renal DNA released into the blood and urine in kidney transplant patients with or without graft rejection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Epigenetic signatures on plasma cell-free DNA to detect kidney allograft rejection in a non-invasive way: development of a 10-plex digital PCR assay.
Velut Y, Poulet G, Bersez T, Boyer P, et al · · 2025 · PMID 41013855 · DOI 10.1186/s40364-025-00834-7

Verify or expand the search:

Other recruiting trials for Transplant Rejection

Currently open trials in the same condition.

NCT05156710 — BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06910527 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Poulet Geoffroy
Last refreshed: 4 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06910527.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing